Originally published byEU-Startups
Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding. This funding was secured from new and existing shareholders. The round was led by new investor Horizon 3 Healthcare, […]
The post Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Bypassing AI guardrails is so easy a script kiddie can do it
5h ago
As Larry Ellison bets the farm, Oracle says it loves AI-written code, just not in OpenJDK
1d ago
AI is 'both the weapon and the target' in latest wave of cyberattacks
1d ago
Helsinki-based Aiforia secures €20 million EIB financing to advance AI-powered cancer diagnostics
1d ago
Unexpected item in the bagging area as Windows Activation error pops up at check-in
3d ago